GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » Shiller PE Ratio

Gentian Diagnostics AS (OSL:GENT) Shiller PE Ratio : (As of Mar. 23, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Gentian Diagnostics AS Shiller PE Ratio Historical Data

The historical data trend for Gentian Diagnostics AS's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS Shiller PE Ratio Chart

Gentian Diagnostics AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gentian Diagnostics AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gentian Diagnostics AS's Shiller PE Ratio

For the Medical Devices subindustry, Gentian Diagnostics AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's Shiller PE Ratio falls into.



Gentian Diagnostics AS Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Gentian Diagnostics AS's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Gentian Diagnostics AS's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=2.09/134.8000*134.8000
=2.090

Current CPI (Dec. 2024) = 134.8000.

Gentian Diagnostics AS Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 96.600 0.000
201412 0.000 98.600 0.000
201509 -0.139 100.600 -0.186
201512 -0.116 100.900 -0.155
201603 -0.076 102.500 -0.100
201606 -0.032 103.800 -0.042
201609 -0.426 104.200 -0.551
201612 -0.246 104.400 -0.318
201703 -0.381 105.000 -0.489
201706 0.029 105.800 0.037
201709 -0.355 105.900 -0.452
201712 -0.377 106.100 -0.479
201803 -0.277 107.300 -0.348
201806 -0.149 108.500 -0.185
201809 -0.038 109.500 -0.047
201812 -0.846 109.800 -1.039
201903 -0.473 110.400 -0.578
201906 -1.321 110.600 -1.610
201909 -0.337 111.100 -0.409
201912 -0.458 111.300 -0.555
202003 -0.359 111.200 -0.435
202006 -0.092 112.100 -0.111
202009 -0.453 112.900 -0.541
202012 -0.229 112.900 -0.273
202103 -0.319 114.600 -0.375
202106 -0.230 115.300 -0.269
202109 -0.440 117.500 -0.505
202112 -0.621 118.900 -0.704
202203 -0.430 119.800 -0.484
202206 -0.194 122.600 -0.213
202209 -0.610 125.600 -0.655
202212 -0.300 125.900 -0.321
202303 -0.040 127.600 -0.042
202306 0.060 130.400 0.062
202309 -0.050 129.800 -0.052
202312 -0.650 131.900 -0.664
202403 0.270 132.600 0.274
202406 0.300 133.800 0.302
202409 0.210 133.700 0.212
202412 2.090 134.800 2.090

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gentian Diagnostics AS  (OSL:GENT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Gentian Diagnostics AS Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gentian Diagnostics AS Business Description

Traded in Other Exchanges
N/A
Address
Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.

Gentian Diagnostics AS Headlines